Email Alert | RSS    帮助

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (5): 509-518.doi: 10.19982/j.issn.1000-6621.20230376

• 论著 • 上一篇    下一篇

2018—2020年结核病定点医院肺外结核和结核性胸膜炎患者次均住院费用及影响因素分析

刘燕飞1, 李涛2, 夏愔愔2, 祝贺3, 赵雁林2, 陈伟2()   

  1. 1北京市疾病预防控制中心结核病预防控制所,北京 100013
    2中国疾病预防控制中心 传染病溯源预警与智能决策全国重点实验室 结核病预防控制中心,北京 102206
    3北京大学中国卫生发展研究中心,北京 100191
  • 收稿日期:2023-10-19 出版日期:2024-05-10 发布日期:2024-04-29
  • 通信作者: 陈伟,Email:chenwei@chinacdc.cn
  • 基金资助:
    中央财政结核病预防控制项目(2428);传染病溯源预警与智能决策全国重点实验室项目

Analysis of average hospitalization costs and factors affecting extrapulmonary tuberculosis and tuberculous pleurisy patients in designated tuberculosis hospitals, 2018—2020

Liu Yanfei1, Li Tao2, Xia Yinyin2, Zhu He3, Zhao Yanlin2, Chen Wei2()   

  1. 1Institute for TB Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing 100013, China
    2National Center for Tuberculosis Control and Prevention, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Centre for Disease Control and Prevention, Beijing 102206, China
    3Peking University China Center for Health Development Studies, Beijing 100191, China
  • Received:2023-10-19 Online:2024-05-10 Published:2024-04-29
  • Contact: Chen Wei, Email: chenwei@chinacdc.cn
  • Supported by:
    Central Finance Tuberculosis Prevention and Control Project(2428);National Key Laboratory Project of Intelligent Tracking and Forecasting for Infectious Disease

摘要:

目的: 分析肺外结核和结核性胸膜炎患者次均住院费用、费用构成及其影响因素,为减轻患者经济负担提供参考。方法: 采用便利抽样方法,从全国东、中、西部各选取3家结核病定点医院。利用医院信息系统收集2018—2020年所有入选医院出院时第一诊断为肺外结核和结核性胸膜炎、年龄≥15岁的2940例患者(共计入院3211例次)相关临床资料,包括人口学特征(性别、年龄、婚姻状况、地域、参保情况等)、临床特征(就诊医院性质及级别、入院时间和途径、转科情况、手术情况、结核病类型、出院时间、住院天数等)和住院费用(包括总费用和各单项费用等),采用非参数秩和检验和多重线性回归模型对患者次均住院费用及其影响因素进行单因素和多因素分析。结果: 2018—2020年,3211例次的次均住院费用中位数(四分位数)为9408.16(5768.50,15540.58)元,以神经系统结核费用(12865.89元)和药品费占比[27.96%(4317.48/15438.94)]为最高,化验费占比次之[18.40%(2841.42/15438.94)]。在药品费用构成中,其他药物的费用占比最高[49.33%(2129.80/4317.48)],其次是二线抗结核药物和一线抗结核药物次均费用[分别为22.80%(984.75/4317.48)和18.52%(799.41/4317.48)]。住院时间为17(9,28)d。多重线性回归模型分析结果显示,次均住院费用与住院天数(β'=0.644,P<0.001)、年龄(β'=0.076,P<0.001)、男性(β'=0.033,P=0.008)、居住在西部地区(β'=0.172,P<0.001)、参保(β'=0.045,P=0.002)、综合医院诊治(β'=0.170,P<0.001)、转科治疗(β'=0.103,P<0.001)、手术治疗(β'=0.208,P<0.001)、结核性胸膜炎(β'=0.047,P<0.001)和骨关节结核(β'=0.067,P<0.001)均呈正相关,与2018年出院(β'=-0.039,P=0.004)、已婚(β'=-0.045,P=0.005)、三级医院诊治(β'=-0.047,P=0.015)、新入院(β'=-0.044,P=0.004)和淋巴结结核(β'=-0.068,P<0.001)均呈负相关。结论: 相对于地方居民收入,肺外结核和结核性胸膜炎患者的住院次均费用仍较高,加剧了患病个体和家庭的经济压力,可在合理控制住院天数、优化费用内部结构、加大医疗保障范围、专科治疗、规范医院诊疗行为等方面制定降低肺外结核患者住院费用的措施。

关键词: 结核,肺外, 住院病人, 医院,专科, 费用,医疗, 因素分析,统计学

Abstract:

Objective: To analyze the average hospitalization costs, cost components and their influencing factors for patients with extrapulmonary tuberculosis (EPTB) and tuberculous pleurisy, in order to reduce the economic burden on patients. Methods: All of 2940 patients (a total of 3211 admissions) aged ≥15 years with EPTB and tuberculous pleurisy discharged from 9 designated tuberculosis hospitals from 2018 to 2020 were selected to collect their demographic characteristics (gender, age, marital status, region, medical insurance, etc.), clinical characteristics (nature and level of hospital, time and route of admission, transfers, surgery, type of tuberculosis, time of discharge, duration of hospitalization, etc.), and hospitalization expenses (total cost and individual costs, etc.). Non-parametric rank sum test was used to analyze the influencing factors of hospitalization expenses; multiple linear regression model was used for multifactor analysis. Results: The median expense of hospitalization for patients with extrapulmonary tuberculosis and tuberculous pleurisy was 9408.16 (IQR: 5768.50, 15540.58) Yuan, the highest median hospitalization expense was for neurological tuberculosis (12865.89 Yuan). In the composition of hospitalization expenses, drug expenses (27.96% (4317.48/15438.94)) account for the highest proportion, followed by the cost of laboratory tests (18.40% (2841.42/15438.94)). Of the drug cost components, the highest proportion of cost was for other drugs (49.33% (2129.80/4317.48)), the followed by second-line anti-tuberculosis drugs (22.80% (984.75/4317.48)) and first-line anti-tuberculosis drugs (18.52% (799.41/4317.48)). Length of stay was 17 (IQR: 9, 28) days. Multiple linear regression model analysis showed that hospitalization costs were significantly associated with the hospitalization days (β'=0.644, P<0.001), age (β'=0.076, P<0.001), male (β'=0.033, P=0.008), living in the West (β'=0.172, P<0.001), insurance participation (β'=0.045, P=0.002), general hospital diagnosis and treatment (β'=0.170, P<0.001), referral for treatment (β'=0.103, P<0.001), surgical treatment (β'=0.208, P<0.001), tuberculosis pleurisy (β'=0.047, P<0.001), and bone and joint tuberculosis (β'=0.067, P<0.001), negative correlation with discharged in 2018 (β'=-0.039, P=0.004), married (β'=-0.045, P=0.005), diagnosis and treatment in tertiary hospitals (β'=-0.047, P=0.015), first admitted (β'=-0.044, P=0.004) and lymph node tuberculosis (β'=-0.068, P<0.001). Conclusion: Compared with the income of the population, the hospitalization costs of patients with extrapulmonary tuberculosis and tuberculous pleurisy are still high, exacerbating the financial burden on individuals and families, and measures to reduce the hospitalization costs of patients with extrapulmonary tuberculosis can be formulated in the areas of reasonable control of hospitalization days, optimization of the structure of costs, increase in the scope of medical care coverage, specialized hospital treatment, and standardization of hospital diagnostic and therapeutic behaviors.

Key words: Extrapulmonary tuberculosis, Inpatients, Hospitals, special, Fees, medical, Factor analysis, statistical

中图分类号: